SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1803-MM, Maintenance, Len vs Len/Dara | 1 | Y | 0 Screening | 1420 | 1283 | 142 | 130 | 72 | 19 | 6 | 08/13/2019 | 322 | 127 |
1283 | 142 | 130 | 72 | 19 | 6 | |||||||||
2 | Y | 1 Lenalidomide | 590 | 66 | 58 | 36 | 7 | 2 | 08/13/2019 | |||||
2 Lenalidomide + Daratumumab | 585 | 71 | 64 | 36 | 9 | 4 | ||||||||
1175 | 137 | 122 | 72 | 16 | 6 | |||||||||
3 | Y | 3 Stop vs Continue Treatment | 190 | 81 | 31 | 15 | 3 | 0 | 08/13/2019 | |||||
190 | 81 | 31 | 15 | 3 | 0 | |||||||||
S2005-WM, Prev. Untreated, I/R +/- Venetoclax | 1 | Y | 1 I+R | 92 | 1 | 1 | 1 | 0 | 0 | 0 | 01/05/2022 | 72 | 25 | |
2 I+R+Venetoclax | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
3 V+R | 3 | 3 | 3 | 3 | 2 | 0 | ||||||||
5 | 4 | 4 | 3 | 2 | 0 | |||||||||
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | 1 | Y | 1 VRD-R | 510 | 10 | 10 | 6 | 3 | 1 | 0 | 10/12/2023 | 183 | 70 | |
2 DRD-R | 11 | 11 | 7 | 4 | 2 | 1 | ||||||||
3 DRD-DR | 9 | 9 | 7 | 4 | 0 | 0 | ||||||||
30 | 30 | 20 | 11 | 3 | 1 | |||||||||
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | 1 | Y | 0 Induction | 338 | 1 | 1 | 1 | 1 | 1 | 0 | 07/01/2024 | 79 | 27 | |
1 | 1 | 1 | 1 | 1 | 0 | |||||||||
Yes | EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 0 | E | Total Registrations | 46 | 17 | 2 | 0 | 0 | 0 | 05/27/2021 | 206 | 81 | |
46 | 17 | 2 | 0 | 0 | 0 | |||||||||
1 | E | Total Registrations | 35 | 13 | 4 | 1 | 0 | 0 | 05/27/2021 | |||||
35 | 13 | 4 | 1 | 0 | 0 | |||||||||
2 | E | Total Registrations | 22 | 13 | 9 | 5 | 2 | 0 | 05/27/2021 | |||||
22 | 13 | 9 | 5 | 2 | 0 | |||||||||
No | EAA173-MYEL, SMM, Rd +/- Daratumumab | 0 | E | Total Registrations | 68 | 17 | 11 | 7 | 1 | 0 | 01/08/2020 | 236 | 98 | |
68 | 17 | 11 | 7 | 1 | 0 | |||||||||
1 | E | Total Registrations | 32 | 9 | 6 | 6 | 0 | 0 | 01/08/2020 | |||||
32 | 9 | 6 | 6 | 0 | 0 | |||||||||
Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | 2 Randomization | 01-Dec-23 | 79 | 27 |
3 Maintenance | 01-Dec-23 | 79 | 27 |